chartexchange

Corvus Pharmaceuticals Inc (CRVS) Q3 2026 Earnings Call Highlights: Strong Cash Runway and Key ...

GuruFocus | Nov 6, 2026 10:15 AM EST

Corvus Pharmaceuticals Inc (CRVS) reported a $20.3 million net loss but holds $202.9 million in cash to fund operations into Q2 2028, with pivotal socolitinib data readouts expected through 2027. Related Stocks: CRVS ,

Read original article